BSE
Your Result on : Company News
Cipla Ltd Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
500087
ISIN Demat
INE059A01026
Book Value (Rs)
432.1356994
NSE Symbol
CIPLA
Divident Yield %
0.92
Market Cap
(Rs In Cr.)
114,720
P/E (TTM)
40.17
EPS (TTM)
35.35
Face Value
(Rs)
2
Date Heading
27-Oct-26 Cipla slips after Q2 PAT drops 35% YoY
27-Oct-26 Cipla consolidated net profit declines 35.05% in the September 2026 qu
05-Oct-26 Cipla Ltd under sustained pressure
29-Sep-26 Cipla to announce Quarterly Result
24-Sep-26 Cipla allots 12,168 equity shares under ESOS
18-Sep-26 Cipla receives ESG rating of 68
04-Sep-26 Invagen Pharmaceuticals enters licensing agreement with Qilu
04-Sep-26 Cipla inks exclusive partnership with Qilu Pharma for commercializing
01-Sep-26 Cipla inks exclusive licensing agreement with SBP Group for ADC Roldit
31-Aug-26 Cipla and SBP Group sign exclusive license agreement for Rolditamig De
04-Aug-26 InvaGen receives EIR report for its facility in Hauppauge, New York
23-Jul-26 Cipla consolidated net profit declines 39.19% in the June 2026 quarter
23-Jul-26 Cipla drops after Q1 PAT tumbles 39% YoY to Rs 789 cr
23-Jul-26 Board of Cipla approves change in senior management
23-Jul-26 Cipla grants 24,709 stock options and ESARs
Risk Factor   |   Terms & Conditions   |   Privacy Policy   |   Disclaimer   |  Sitemap 
Important Links:   SEBI   |   NSE   |   BSE   |   MCX   |   NCDEX   |   NSDL   |   CDSL  |   FMC
BSE Delayed market data sourced at 5 minutes – www.bseindia.com
SMS FINANCIAL SERVICES P. LTD -NSE SEBI No. AP1413004363 | BSE SEBI No. AP01091801121968
Ganesh S Shanbhag – AMFI Registered Mutual Fund Distributor. Registration Number – ARN-0988 – Valid Till 01/JUL/ 2027, Date of initial registration: 02/DEC/2004
2017-18 © SMS Financial Services. All rights reserved. Designed, Developed , Maintained and Content Powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)